Biolife Solutions Stock Performance
| BLFS Stock | USD 21.91 0.35 1.57% |
The firm shows a Beta (market volatility) of 1.25, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioLife Solutions will likely underperform. At this point, BioLife Solutions has a negative expected return of -0.29%. Please make sure to confirm BioLife Solutions' information ratio, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if BioLife Solutions performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days BioLife Solutions has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in May 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (1.57) | Five Day Return 4.93 | Year To Date Return (16.31) | Ten Year Return 958.51 | All Time Return (79.13) |
Last Split Factor 1:14 | Last Split Date 2014-01-29 |
1 | Disposition of 17604 shares by Aby Mathew of BioLife Solutions at 20.05 subject to Rule 16b-3 | 02/28/2025 |
2 | Disposition of 4151 shares by Troy Wichterman of BioLife Solutions at 25.0 subject to Rule 16b-3 | 03/11/2025 |
3 | Disposition of 7324 shares by Aebersold Sarah of BioLife Solutions at 26.34 subject to Rule 16b-3 | 03/12/2025 |
4 | Disposition of 2695 shares by Aebersold Sarah of BioLife Solutions at 25.44 subject to Rule 16b-3 | 03/17/2025 |
5 | Disposition of 324 shares by Karen Foster of BioLife Solutions at 25.46 subject to Rule 16b-3 | 03/19/2025 |
6 | BioLife Solutions Inc Appoints Cathy Coste as Director and Audit Committee Chair | 03/21/2025 |
7 | Cannell Spears LLC Sells 1,322 Shares of BioLife Solutions, Inc. | 04/01/2025 |
8 | BioLife Solutions, Inc. CFO Troy Wichterman Sells 25,687 Shares of Stock | 04/04/2025 |
9 | Massachusetts Financial Services Co. MA Takes Position in BioLife Solutions, Inc. | 04/07/2025 |
10 | Is BioLife Solutions Navigating a New Phase in Biotech Sector Activity | 04/09/2025 |
11 | BioLife Solutions Upgraded at StockNews.com | 04/11/2025 |
| Begin Period Cash Flow | 35.4 M |
BioLife Solutions Relative Risk vs. Return Landscape
If you would invest 2,748 in BioLife Solutions on January 18, 2025 and sell it today you would lose (557.00) from holding BioLife Solutions or give up 20.27% of portfolio value over 90 days. BioLife Solutions is currently does not generate positive expected returns and assumes 3.685% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than BioLife, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioLife Solutions Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioLife Solutions' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioLife Solutions, and traders can use it to determine the average amount a BioLife Solutions' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0791
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BLFS |
Estimated Market Risk
| 3.69 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.29 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioLife Solutions is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioLife Solutions by adding BioLife Solutions to a well-diversified portfolio.
BioLife Solutions Fundamentals Growth
BioLife Stock prices reflect investors' perceptions of the future prospects and financial health of BioLife Solutions, and BioLife Solutions fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioLife Stock performance.
| Return On Equity | -0.0332 | ||||
| Return On Asset | -0.011 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | (0.40) % | ||||
| Current Valuation | 967.38 M | ||||
| Shares Outstanding | 47.55 M | ||||
| Price To Earning | 173.59 X | ||||
| Price To Book | 2.99 X | ||||
| Price To Sales | 12.87 X | ||||
| Revenue | 82.25 M | ||||
| Gross Profit | 53.67 M | ||||
| EBITDA | 1.53 M | ||||
| Net Income | (20.18 M) | ||||
| Cash And Equivalents | 46.55 M | ||||
| Cash Per Share | 1.09 X | ||||
| Total Debt | 25.18 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 3.55 X | ||||
| Book Value Per Share | 7.44 X | ||||
| Cash Flow From Operations | 8.43 M | ||||
| Earnings Per Share | (0.25) X | ||||
| Market Capitalization | 1.06 B | ||||
| Total Asset | 399.49 M | ||||
| Retained Earnings | (335.1 M) | ||||
| Working Capital | 116.03 M | ||||
| Current Asset | 6.97 M | ||||
| Current Liabilities | 1.73 M | ||||
About BioLife Solutions Performance
Assessing BioLife Solutions' fundamental ratios provides investors with valuable insights into BioLife Solutions' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the BioLife Solutions is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 432.20 | 238.03 | |
| Return On Tangible Assets | (0.11) | (0.12) | |
| Return On Capital Employed | (0.02) | (0.02) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.06) | (0.06) |
Things to note about BioLife Solutions performance evaluation
Checking the ongoing alerts about BioLife Solutions for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioLife Solutions help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioLife Solutions generated a negative expected return over the last 90 days | |
| BioLife Solutions has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 82.25 M. Net Loss for the year was (20.18 M) with profit before overhead, payroll, taxes, and interest of 53.67 M. | |
| BioLife Solutions has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: BioLife Solutions Upgraded at StockNews.com |
- Analyzing BioLife Solutions' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioLife Solutions' stock is overvalued or undervalued compared to its peers.
- Examining BioLife Solutions' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioLife Solutions' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioLife Solutions' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioLife Solutions' stock. These opinions can provide insight into BioLife Solutions' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioLife Stock Analysis
When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.